

## 16.2. Patient Data Listings

### 16.2.1 Discontinued Subjects

Number	Title
<a href="#">Listing 16.2.1</a>	Subject Disposition

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0101-0002	ADIPemPlatinum	Y/Y/Y	28FEB2018	28SEP2018 (213)	Progressive Disease: Clinical Progression	Death, Cause of Death: Unknown	28SEP2018
0101-0003	PlaceboPemPlatinum	Y/Y/Y	28MAR2018	09AUG2018 (135)	Progressive Disease: Clinical Progression	Death, Cause of Death: Unknown	09AUG2018
0101-0004	ADIPemPlatinum	Y/Y/Y	14MAY2018	12DEC2018 (213)	Progressive Disease: Clinical Progression	Death, Cause of Death: Other, RESPIRATORY DISTRESS/CARDIAC ARREST	12DEC2018
0101-0006	PlaceboPemPlatinum	Y/Y/Y	08APR2019	22SEP2020 (534)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Other, RESPIRATORY FAILURE	22SEP2020
0101-0008	ADIPemPlatinum	Y/Y/Y	13MAY2019	08JUN2022 (1123)	Adverse Event: ANAPHYLAXIS	Death, Cause of Death: Malignant disease	08JUN2022
0101-0009	ADIPemPlatinum	Y/Y/Y	19JUN2019	06OCT2019 (110)	Progressive Disease: Clinical Progression	Death, Cause of Death: Unknown	06OCT2019
0101-0010	PlaceboPemPlatinum	Y/Y/Y	29JUL2019	04AUG2022 (1103)	Adverse Event: DYSPNEA	Other: STUDY COMPLETION	
0101-0011	ADIPemPlatinum	Y/Y/Y	04SEP2019	24MAY2020 (264)	Progressive Disease: Clinical Progression	Death, Cause of Death: Unknown	24MAY2020
0102-0001	ADIPemPlatinum	Y/Y/Y	06SEP2017	20SEP2019 (745)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Unknown	20SEP2019
0102-0002	ADIPemPlatinum	Y/Y/Y	27DEC2017	17AUG2022 (1695)	Progressive Disease: PD proven by local imaging review	Other: THE REASON FOR STUDY TERMINATION IS "OTHER" AND THE LAST DATE OF CONTACT CAN BE THE SURVIVAL FU DATE	
0102-0003	PlaceboPemPlatinum	Y/Y/Y	31JAN2018	03MAY2018 (93)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	03MAY2018

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0102-0004	PlaceboPemPlatinum	Y/Y/Y	13FEB2018	13JUL2018 (151)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	13JUL2018
0102-0005	PlaceboPemPlatinum	Y/Y/Y	18APR2018	27AUG2018 (132)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	27AUG2018
0102-0006	PlaceboPemPlatinum	Y/Y/Y	09JAN2019	21FEB2020 (409)	Progressive Disease: PD proven by local imaging review, Other: YES	Death, Cause of Death: Malignant disease	21FEB2020
0102-0007	ADIPemPlatinum	Y/Y/Y	17JUL2019	16APR2021 (640)	Withdrawal from Treatment by Subject: THE LAST DATE OF SCAN WERE DONE ON 08/21/2019 WHICH SHOWED STABLE DISEASE	Death, Cause of Death: Malignant disease	16APR2021
0102-0008	PlaceboPemPlatinum	Y/Y/Y	18SEP2019	03DEC2019 (77)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: SAE	03DEC2019
0102-0009	PlaceboPemPlatinum	Y/Y/Y	30SEP2019	20MAY2020 (234)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Unknown	20MAY2020
0102-0010	ADIPemPlatinum	Y/Y/Y	22JAN2020	01JUL2020 (162)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 21MAY2020	Death, Cause of Death: Unknown	01JUL2020
0102-0011	ADIPemPlatinum	Y/Y/Y	26FEB2020	18JUN2020 (114)	Progressive Disease: Clinical Progression, Date of Scan with PD or Last Scan with SD: 01APR2020	Death, Cause of Death: Unknown	18JUN2020
0102-0012	ADIPemPlatinum	Y/Y/Y	04MAR2020	30AUG2021 (545)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 20OCT2020	Death, Cause of Death: Malignant disease	30AUG2021
0102-0013	PlaceboPemPlatinum	Y/Y/Y	11MAR2020	06AUG2020 (149)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 27MAY2020	Death, Cause of Death: Unknown	06AUG2020
0102-0014	ADIPemPlatinum	Y/Y/Y	27APR2020	19FEB2021 (299)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 03FEB2021	Death, Cause of Death: Malignant disease	19FEB2021

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0102-0015	ADIPemPlatinum	Y/Y/Y	21JUL2020	15DEC2020 (148)	Adverse Event: DYSPNEA, Other: STABLE DISEASE, Date of Scan with PD or Last Scan with SD: 26SEP2020	Death, Cause of Death: Malignant disease	15DEC2020
0103-0001	ADIPemPlatinum	Y/Y/Y	06SEP2017	14SEP2017 (9)	Death, Cause of Death: SAE, CARDIAC ARREST	Death, Cause of Death: SAE	14SEP2017
0103-0003	ADIPemPlatinum	Y/Y/Y	07MAR2018	21JAN2019 (321)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Unknown	21JAN2019
0103-0005	ADIPemPlatinum	Y/Y/Y	14MAY2018	20MAY2018 (7)	Death, Cause of Death: Malignant disease	Death, Cause of Death: Malignant disease	20MAY2018
0103-0006	PlaceboPemPlatinum	Y/Y/Y	14JUN2018	12JUN2019 (364)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	12JUN2019
0103-0009	ADIPemPlatinum	Y/Y/Y	14AUG2019	08APR2020 (239)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	08APR2020
0103-0010	PlaceboPemPlatinum	Y/Y/Y	25MAY2020	30DEC2020 (220)	Adverse Event: DEHYDRATION, Date of Scan with PD or Last Scan with SD: 22NOV2020	Death, Cause of Death: Malignant disease	30DEC2020
0104-0001	PlaceboPemPlatinum	Y/Y/Y	11APR2018	03NOV2019 (572)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	03NOV2019
0104-0003	PlaceboPemPlatinum	Y/Y/Y	23JAN2019	15JUN2019 (144)	Adverse Event: THROMBOEMBOLIC EVENT RIGHT LOWER EXTREMITY	Death, Cause of Death: Malignant disease	15JUN2019
0104-0004	ADIPemPlatinum	Y/Y/Y	17JUN2019	08AUG2022 (1149)	Progressive Disease: PD proven by central imaging review	Other: STUDY TERMINATION	
0104-0006	ADIPemPlatinum	Y/Y/Y	04NOV2019	01MAY2020 (180)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	01MAY2020
0107-0001	ADIPemPlatinum	Y/Y/Y	10APR2018	31JAN2020 (662)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	31JAN2020
0107-0002	PlaceboPemPlatinum	Y/Y/Y	22AUG2018	09JUN2021 (1023)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	09JUN2021
0107-0003	ADIPemPlatinum	Y/Y/Y	18DEC2018	19DEC2018 (2)	Withdrawal from Treatment by Subject	Subject Decision to Withdraw Consent	08FEB2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0107-0004	ADIPemPlatinum	Y/Y/Y	18DEC2018	01JAN2020 (380)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	01JAN2020
0107-0005	ADIPemPlatinum	Y/Y/Y	19FEB2019	24OCT2019 (248)	Progressive Disease: PD proven by local imaging review	Other: GOING BACK TO LAS VEGAS AND DOES NOT WANT TO BE FOLLOWED	
0107-0006	ADIPemPlatinum	Y/Y/Y	13MAR2019	13AUG2019 (154)	Other: CT SCAN PERFORMED 31MAY2019 SHOWING STABLE DISEASE	Death, Cause of Death: Malignant disease	13AUG2019
0107-0007	ADIPemPlatinum	Y/Y/Y	21OCT2019	09DEC2019 (50)	Withdrawal from Treatment by Subject	Other: SPOKE WITH PATIENT AND HE ADVISED HE HAS MOVED BACK TO OREGON AND WILL NOT BE FOLLOWING UP CARE WITH OUR OFFICE AND HE WOULD ESTABLISH CARE WITH SOMEONE IN OREGON.	01JAN2020
0107-0008	ADIPemPlatinum	Y/Y/Y	29OCT2019	15SEP2020 (323)	Progressive Disease: Clinical Progression, Other: OVERALL RESPONSE=STABLE DISEASELAST SCAN=11AUG2020	Death, Cause of Death: Malignant disease	15SEP2020
0107-0010	PlaceboPemPlatinum	Y/Y/Y	25NOV2019	01APR2021 (494)	Progressive Disease: PD proven by local imaging review, Other: OVERALL RESPONSE=PDLAST SCAN = 14MAY2020	Death, Cause of Death: Malignant disease	01APR2021
0107-0011	PlaceboPemPlatinum	Y/Y/Y	01JUN2020	06SEP2020 (98)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 10AUG2020	Death, Cause of Death: Malignant disease	06SEP2020
0108-0002	PlaceboPemPlatinum	Y/Y/Y	30JAN2019	14MAR2019 (44)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	14MAR2019
0108-0003	ADIPemPlatinum	Y/Y/Y	13MAR2019	08MAY2019 (57)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	08MAY2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0108-0004	PlaceboPemPlatinum	Y/Y/Y	01MAY2019	15JUL2019 (76)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	15JUL2019
0108-0006	PlaceboPemPlatinum	Y/Y/Y	30OCT2019	05DEC2021 (768)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	05DEC2021
0108-0007	ADIPemPlatinum	Y/Y/Y	05FEB2020	10AUG2022 (918)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 26JAN2021	Other: STUDY COMPLETION	
0108-0009	PlaceboPemPlatinum	Y/Y/Y	04MAR2020	07APR2021 (400)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 21OCT2020	Death, Cause of Death: Malignant disease	07APR2021
0110-0001	ADIPemPlatinum	Y/Y/Y	31JUL2018	08FEB2021 (924)	Progressive Disease: PD proven by central imaging review, Other: OCT 23 2018	Death, Cause of Death: Malignant disease	08FEB2021
0110-0002	ADIPemPlatinum	Y/Y/Y	12FEB2019	08OCT2019 (239)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	08OCT2019
0112-0002	ADIPemPlatinum	Y/Y/Y	26AUG2019	24SEP2019 (30)	Adverse Event: ATRIAL FIBRILLATION	Subject Decision to Withdraw Consent	11OCT2019
0112-0003	PlaceboPemPlatinum	Y/Y/Y	24SEP2019	04AUG2020 (316)	Progressive Disease: Clinical Progression	Death, Cause of Death: Unknown	04AUG2020
0201-0001	PlaceboPemPlatinum	Y/Y/Y	02AUG2017	17MAY2018 (289)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	17MAY2018
0201-0002	PlaceboPemPlatinum	Y/Y/Y	09AUG2017	10OCT2017 (63)	Death, Cause of Death: Malignant disease, CHEST SEPSIS	Death, Cause of Death: Malignant disease	10OCT2017
0201-0004	PlaceboPemPlatinum	Y/Y/Y	06SEP2017	28NOV2017 (84)	Withdrawal from Treatment by Subject: HE DOESN'T WANT TO RECEIVE TREATMENT AND WOULD BE HAVING A PALLIATIVE CARE NURSE.	Death, Cause of Death: Malignant disease	28NOV2017
0201-0005	ADIPemPlatinum	Y/Y/Y	13SEP2017	09DEC2018 (453)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	09DEC2018

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0201-0006	ADIPemPlatinum	Y/Y/Y	13SEP2017	08MAR2018 (177)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	08MAR2018
0201-0007	ADIPemPlatinum	Y/Y/Y	11OCT2017	20MAY2019 (587)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	20MAY2019
0201-0008	ADIPemPlatinum	Y/Y/Y	25JUL2018	18SEP2019 (421)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	18SEP2019
0201-0009	PlaceboPemPlatinum	Y/Y/Y	25OCT2017	09OCT2019 (715)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	09OCT2019
0201-0011	PlaceboPemPlatinum	Y/Y/Y	13DEC2017	04OCT2019 (661)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Unknown	04OCT2019
0201-0013	ADIPemPlatinum	Y/Y/Y	31JAN2018	16AUG2018 (198)	Withdrawal from Treatment by Subject: PATIENT CALLED ON 09/JUL/2019 TO INFORM THAT HE WOULD NOT LIKE TO CONTINUE WITH TRIAL. PATIENT WANTED TO BE WITH FAMILY.	Death, Cause of Death: Malignant disease	16AUG2018
0201-0014	PlaceboPemPlatinum	Y/Y/Y	14FEB2018	25MAY2018 (101)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	25MAY2018
0201-0015	ADIPemPlatinum	Y/Y/Y	14MAR2018	05MAY2020 (784)	Adverse Event: ALLERGIC REACTION	Death, Cause of Death: Malignant disease	05MAY2020
0201-0016	PlaceboPemPlatinum	Y/Y/Y	04APR2018	26MAR2019 (357)	Death, Cause of Death: Malignant disease	Death, Cause of Death: Malignant disease	26MAR2019
0201-0017	PlaceboPemPlatinum	Y/Y/Y	25APR2018	20NOV2018 (210)	Progressive Disease: PD proven by local imaging review, Other: DATE OF PD ON SCAN DATED 07AUG2018	Death, Cause of Death: Unknown	20NOV2018
0201-0018	ADIPemPlatinum	Y/Y/Y	01MAY2018	07NOV2019 (556)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	07NOV2019
0201-0019	ADIPemPlatinum	Y/Y/Y	09MAY2018	13JUL2019 (431)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Unknown	13JUL2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0201-0020	PlaceboPemPlatinum	Y/Y/Y	06JUN2018	16APR2019 (315)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Unknown	16APR2019
0201-0021	PlaceboPemPlatinum	Y/Y/Y	27JUN2018	29DEC2018 (186)	Progressive Disease: PD proven by local imaging review, Other: DATE OF SCAN SHOWING PROGRESSION 05/12/2018	Death, Cause of Death: Malignant disease	29DEC2018
0201-0022	PlaceboPemPlatinum	Y/Y/Y	04JUL2018	08AUG2022 (1497)	Withdrawal from Treatment by Subject	Other: STUDY COMPLETION	
0201-0023	ADIPemPlatinum	Y/Y/Y	18JUL2018	04NOV2019 (475)	Progressive Disease: PD proven by local imaging review, Other: LAST SCAN SHOWING SD WAS 25/06/2019. PATIENT SHOWED PD AT ANOTHER HOSPITAL SITE ON HEAD SCAN	Death, Cause of Death: Malignant disease	04NOV2019
0201-0024	ADIPemPlatinum	Y/Y/Y	01AUG2018	03FEB2019 (187)	Progressive Disease: Clinical Progression, Other: 28/NOV/2018	Death, Cause of Death: Unknown	03FEB2019
0201-0025	PlaceboPemPlatinum	Y/Y/Y	14NOV2018	25OCT2020 (712)	Progressive Disease: Clinical Progression, Other: 27/08/2019 DATE OF LAST SCAN WITH STABLE DISEASE	Death, Cause of Death: Other, COVID-19 ON A BACKGROUND OF MESOTHELIOMA	25OCT2020
0201-0026	PlaceboPemPlatinum	Y/Y/Y	05SEP2018	05JAN2019 (123)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Unknown	05JAN2019
0201-0027	PlaceboPemPlatinum	Y/Y/Y	02OCT2018	16JUL2019 (288)	Adverse Event: CHEST INFECTION, Other: DATE OF LAST SCAN SHOWING STABLE DISEASE WAS 11/12/2018	Death, Cause of Death: Unknown	16JUL2019
0201-0028	PlaceboPemPlatinum	Y/Y/Y	17OCT2018	07MAY2019 (203)	Progressive Disease: PD proven by local imaging review, Other: 21/12/2018 CT CAP SHOWING PD	Death, Cause of Death: Malignant disease	07MAY2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug



Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )		Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0201-0030	PlaceboPemPlatinum	Y/Y/Y	17OCT2018	13MAR2019 (148)	Progressive Disease: PD proven by local imaging review, Other: LAST SCAN TO SHOW RESPONSE WAS 02/01/2019. THE DATE OF THE SCAN WITH DISEASE PROGRESSION WAS PERFORMED AT ANOTHER HOSPITAL AND IT IS UNCLEAR FROM THE NOTES WHAT DATE THIS SCAN WAS PERFORMED	Death, Cause of Death: Malignant disease		13MAR2019
0201-0031	ADIPemPlatinum	Y/Y/Y	31OCT2018	23JUN2022 (1332)	Other: HAS COMPLETED THE TRIAL. DATE OF LAST SCAN SHOWING STABLE DISEASE- 30/10/2020	Other: STUDY COMPLETION		
0201-0033	ADIPemPlatinum	Y/Y/Y	16JAN2019	12FEB2020 (393)	Progressive Disease: Clinical Progression, Other: DATE OF SCAN WITH PD 10/07/2019	Death, Cause of Death: Malignant disease		12FEB2020
0201-0034	ADIPemPlatinum	Y/Y/Y	05DEC2018	03AUG2022 (1338)	Other: TRIAL COMPLETED. LAST CT SCAN SHOWING STABLE DISEASE WAS 05/NOV/2020	Other: STUDY COMPLETION		
0201-0035	PlaceboPemPlatinum	Y/Y/Y	05DEC2018	26AUG2019 (265)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease		26AUG2019
0201-0036	ADIPemPlatinum	Y/Y/Y	05DEC2018	09MAY2019 (156)	Progressive Disease: PD proven by local imaging review, Other: 22/01/2019 SCAN DATE	Death, Cause of Death: Unknown		09MAY2019
0201-0038	ADIPemPlatinum	Y/Y/Y	16JAN2019	11MAR2020 (421)	Progressive Disease: PD proven by local imaging review, Other: SCAN SHOWING PD 01/10/2019	Death, Cause of Death: Malignant disease		11MAR2020
0201-0039	ADIPemPlatinum	Y/Y/Y	30JAN2019	22SEP2020 (602)	Progressive Disease: PD proven by local imaging review, Other: DATE OF SCAN WITH PD: 20/08/2019	Death, Cause of Death: Malignant disease		22SEP2020
0201-0040	PlaceboPemPlatinum	Y/Y/Y	12FEB2019	27MAR2020 (410)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Other, COVID-19 PNEUMONIA WITH UNDERLYING SARC MESO		27MAR2020

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0201-0041	ADIPemPlatinum	Y/Y/Y	03APR2019	01NOV2020 (579)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	01NOV2020
0201-0043	ADIPemPlatinum	Y/Y/Y	08MAY2019	03AUG2022 (1184)	Progressive Disease: PD proven by central imaging review	Other: STUDY COMPLETION	
0201-0044	PlaceboPemPlatinum	Y/Y/Y	15MAY2019	14JUN2020 (397)	Progressive Disease: PD proven by local imaging review, Other: DATE OF SCAN SHOWING DISEASE PROGRESSION 01/04/2020	Death, Cause of Death: Malignant disease	14JUN2020
0201-0045	PlaceboPemPlatinum	Y/Y/Y	24APR2019	28NOV2021 (950)	Progressive Disease: PD proven by local imaging review, Other: DATE OF LAST SCAN WHILE ON TRIAL WAS 19/08/2020 LOCAL REVIEW DEEMED THIS SCAN TO SHOW PROGRESSIVE DISEASE	Death, Cause of Death: Other, MALIGNANT DISEASE AND SEPSIS	28NOV2021
0201-0046	ADIPemPlatinum	Y/Y/Y	15MAY2019	13APR2020 (335)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	13APR2020
0201-0047	PlaceboPemPlatinum	Y/Y/Y	15MAY2019	20OCT2019 (159)	Adverse Event: LEFT SIDE NON- CARDIAC CHEST PAIN	Death, Cause of Death: Malignant disease	20OCT2019
0201-0048	PlaceboPemPlatinum	Y/Y/Y	04JUN2019	03DEC2019 (183)	Adverse Event: GOUT WITH CRYSTALS	Death, Cause of Death: Malignant disease	03DEC2019
0201-0049	ADIPemPlatinum	Y/Y/Y	25JUN2019	01NOV2019 (130)	Adverse Event: DIARRHOEA	Death, Cause of Death: Malignant disease	01NOV2019
0201-0050	PlaceboPemPlatinum	Y/Y/Y	23JUL2019	02AUG2020 (377)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	02AUG2020
0201-0051	PlaceboPemPlatinum	Y/Y/Y	02JUL2019	23FEB2020 (237)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	23FEB2020
0201-0052	PlaceboPemPlatinum	Y/Y/Y	17JUL2019	02NOV2019 (109)	Progressive Disease: Clinical Progression, Other: LAST SCAN: 02/OCT/2019 WITH AN OVERALL RESPONSE OF STABLE DISEASE	Death, Cause of Death: Malignant disease	02NOV2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0201-0053	ADIPemPlatinum	Y/Y/Y	17JUL2019	01JUL2021 (716)	Progressive Disease: PD proven by local imaging review, Other: LAST CT SCAN TO SHOW OVERALL SD LOCAL REVIEW WAS ON 06/05/2020, FIRST SCAN TO SHOW PD WAS 01/07/2020. LAST SCAN TO SHOW PD WAS 24/02/2021.	Death, Cause of Death: Malignant disease	01JUL2021
0201-0054	PlaceboPemPlatinum	Y/Y/Y	21AUG2019	26SEP2020 (403)	Progressive Disease: PD proven by local imaging review, Other: THE LAST SCAN THE PATIENT HAD ON TRIAL WAS ON 03/06/2020 AND THIS SHOWED PROGRESSIVE DISEASE THROUGH LOCAL REVIEW	Death, Cause of Death: Malignant disease	26SEP2020
0201-0056	ADIPemPlatinum	Y/Y/Y	18SEP2019	08JAN2020 (113)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	08JAN2020
0201-0057	PlaceboPemPlatinum	Y/Y/Y	10FEB2020	01APR2020 (52)	Adverse Event: ANEMIA, Date of Scan with PD or Last Scan with SD: 28FEB2020	Death, Cause of Death: Malignant disease	01APR2020
0201-0058	ADIPemPlatinum	Y/Y/Y	25FEB2020	08MAY2020 (74)	Adverse Event: EMPYEMA, Date of Scan with PD or Last Scan with SD: 06APR2020	Death, Cause of Death: Malignant disease	08MAY2020
0201-0060	PlaceboPemPlatinum	Y/Y/Y	28APR2021	31JUL2021 (95)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 02JUL2021	Death, Cause of Death: Malignant disease	31JUL2021
0201-0061	PlaceboPemPlatinum	Y/Y/Y	30JUN2021	21SEP2021 (84)	Death, Cause of Death: SAE, BRONCHOPNEUMONIA, Date of Scan with PD or Last Scan with SD: 18AUG2021	Death, Cause of Death: SAE	21SEP2021
0202-0001	PlaceboPemPlatinum	Y/Y/Y	04APR2018	21JAN2019 (293)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	21JAN2019
0202-0002	ADIPemPlatinum	Y/Y/Y	12SEP2018	18JUN2019 (280)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	18JUN2019
0202-0003	ADIPemPlatinum	Y/Y/Y	21MAY2019	14SEP2021 (848)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	14SEP2021

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0202-0004	ADIPemPlatinum	Y/Y/Y	08MAY2019	17AUG2022 (1198)	Other: COMPLETION OF 2 YEARS TREATMENT- CT 21/04/21 SHOWS STABLE DISEASE	Other: STUDY COMPLETED	
0202-0005	PlaceboPemPlatinum	Y/Y/Y	13NOV2019	29JUN2020 (230)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	29JUN2020
0202-0007	PlaceboPemPlatinum	Y/Y/Y	03FEB2021	17APR2021 (74)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 09MAR2021	Death, Cause of Death: Unknown	17APR2021
0203-0001	ADIPemPlatinum	Y/Y/Y	05DEC2017	17MAY2018 (164)	Adverse Event: HYPERCALCAEMIA SECONDARY TO METASTATIC BONE LESIONS, Other: LOCAL CT SCAN DONE ON 28/03/2018 CONFIRMED SLOW DISEASE PROGRESSION	Death, Cause of Death: Unknown	17MAY2018
0203-0002	PlaceboPemPlatinum	Y/Y/Y	02JAN2018	16MAY2021 (1231)	Withdrawal from Treatment by Subject: LAST SCAN ON 09/05/2018 SHOWING STABLE DISEASE	Death, Cause of Death: Malignant disease	16MAY2021
0203-0004	ADIPemPlatinum	Y/Y/Y	21FEB2018	08MAY2018 (77)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	08MAY2018
0203-0005	ADIPemPlatinum	Y/Y/Y	04APR2018	20MAY2019 (412)	Progressive Disease: PD proven by local imaging review, Other: PROGRESSION OF DISEASE REPORTED ON CT SCAN DATED 03/OCTOBER/2018	Death, Cause of Death: Malignant disease	20MAY2019
0203-0006	PlaceboPemPlatinum	Y/Y/Y	02MAY2018	05JUN2018 (35)	Death, Cause of Death: Other, CARDIAC ARREST	Death, Cause of Death: Other, CARDIAC ARREST	05JUN2018
0203-0008	PlaceboPemPlatinum	Y/Y/Y	08AUG2018	03SEP2019 (392)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Unknown	03SEP2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0203-0009	PlaceboPemPlatinum	Y/Y/Y	29AUG2018	23FEB2019 (179)	Progressive Disease: PD proven by local imaging review, Other: DATE OF LAST SCAN OF CHEST/ABDO/PELVIS SHOWING STABLE DISEASE WAS 02/JANUARY/2019. HEAD SCAN 31/JANUARY/2019 SHOWS BRAIN METS.	Death, Cause of Death: Malignant disease	23FEB2019
0203-0010	ADIPemPlatinum	Y/Y/Y	09JAN2019	18OCT2019 (283)	Adverse Event: ACUTE KIDNEY INJURY STAGE 1	Death, Cause of Death: Unknown	18OCT2019
0203-0013	ADIPemPlatinum	Y/Y/Y	13MAR2019	25JUL2022 (1231)	Withdrawal from Treatment by Subject: SCAN PERFORMED ON 22-OCT-2020 SHOWED STABLE DISEASE.	Other: SUBJECT COMPLETED STUDY	
0203-0014	ADIPemPlatinum	Y/Y/Y	24JUL2019	16JUL2020 (359)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Unknown	16JUL2020
0203-0015	PlaceboPemPlatinum	Y/Y/Y	31JUL2019	08JUN2020 (314)	Withdrawal from Treatment by Subject	Death, Cause of Death: Unknown	08JUN2020
0203-0016	PlaceboPemPlatinum	Y/Y/Y	21AUG2019	28FEB2020 (192)	Death, Cause of Death: SAE, STROKE	Death, Cause of Death: SAE, SAE 018	28FEB2020
0203-0018	PlaceboPemPlatinum	Y/Y/Y	15JAN2020	13FEB2020 (30)		Death, Cause of Death: SAE, SAE002	13FEB2020
0203-0019	ADIPemPlatinum	Y/Y/Y	16DEC2020	17FEB2021 (64)	Physician Decision, Date of Scan with PD or Last Scan with SD: 09DEC2020	Death, Cause of Death: Malignant disease	17FEB2021
0204-0001	PlaceboPemPlatinum	Y/Y/Y	16MAY2018	20FEB2019 (281)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	20FEB2019
0204-0002	ADIPemPlatinum	Y/Y/Y	11JUL2018	28DEC2018 (171)	Adverse Event: FATIGUE	Death, Cause of Death: Malignant disease	28DEC2018
0204-0003	PlaceboPemPlatinum	Y/Y/Y	01AUG2018	25NOV2018 (117)	Progressive Disease: Clinical Progression	Death, Cause of Death: Malignant disease	25NOV2018
0204-0004	PlaceboPemPlatinum	Y/Y/Y	21AUG2018	08NOV2018 (80)	Death, Cause of Death: Malignant disease	Death, Cause of Death: Malignant disease	08NOV2018

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0204-0005	ADIPemPlatinum	Y/Y/Y	19SEP2018	18JUL2020 (669)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	18JUL2020
0204-0006	ADIPemPlatinum	Y/Y/Y	05DEC2018	27APR2019 (144)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	27APR2019
0204-0007	ADIPemPlatinum	Y/Y/Y	30JAN2019	14SEP2019 (228)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	14SEP2019
0204-0008	PlaceboPemPlatinum	Y/Y/Y	06FEB2019	02MAY2020 (452)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	02MAY2020
0204-0009	PlaceboPemPlatinum	Y/Y/Y	06MAR2019	20JUN2020 (473)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	20JUN2020
0204-0010	ADIPemPlatinum	Y/Y/Y	07AUG2019	06JAN2020 (153)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	06JAN2020
0204-0011	ADIPemPlatinum	Y/Y/Y	18SEP2019	15MAY2020 (241)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	15MAY2020
0205-0001	ADIPemPlatinum	Y/Y/Y	03JUL2018	06JUL2019 (369)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	06JUL2019
0205-0002	PlaceboPemPlatinum	Y/Y/Y	15APR2019	21NOV2019 (221)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	21NOV2019
0205-0005	PlaceboPemPlatinum	Y/Y/Y	27AUG2019	09APR2020 (227)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	09APR2020
0205-0006	PlaceboPemPlatinum	Y/Y/Y	22OCT2019	20NOV2019 (30)	Adverse Event: PNEUMONIA	Death, Cause of Death: Malignant disease	20NOV2019
0207-0001	ADIPemPlatinum	Y/Y/Y	17SEP2018	30SEP2018 (14)	Adverse Event: NEUTROPENIC SEPSIS	Death, Cause of Death: SAE	30SEP2018
0207-0002	PlaceboPemPlatinum	Y/Y/Y	27NOV2018	24MAY2019 (179)	Adverse Event: EXACERBATION OF DYSPNEA	Death, Cause of Death: Malignant disease	24MAY2019
0207-0003	ADIPemPlatinum	Y/Y/Y	08JUL2019	12OCT2019 (97)	Progressive Disease: PD proven by central imaging review, Other: PD ON CENTRAL REVIEW	Death, Cause of Death: Malignant disease	12OCT2019
0207-0004	PlaceboPemPlatinum	Y/Y/Y	06JAN2020	27JUN2020 (174)	Physician Decision	Death, Cause of Death: Malignant disease	27JUN2020

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0208-0001	ADIPemPlatinum	Y/Y/Y	14MAY2018	22JAN2019 (254)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	22JAN2019
0208-0002	ADIPemPlatinum	Y/Y/Y	04SEP2018	24FEB2019 (174)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	24FEB2019
0208-0003	ADIPemPlatinum	Y/Y/Y	14NOV2018	05JAN2019 (53)	Progressive Disease: PD proven by local imaging review, Other: PD SCAN 21.12.2018	Death, Cause of Death: SAE	05JAN2019
0208-0004	PlaceboPemPlatinum	Y/Y/Y	27MAR2019	03AUG2019 (130)	Progressive Disease: PD proven by local imaging review, Other: PD MRI SCAN 30/07/2019	Death, Cause of Death: Malignant disease	03AUG2019
0208-0006	ADIPemPlatinum	Y/Y/Y	20MAY2019	19OCT2020 (519)	Progressive Disease: PD proven by local imaging review, Other: PROGRESSION SCAN 25.09.2019	Death, Cause of Death: Malignant disease	19OCT2020
0208-0007	ADIPemPlatinum	Y/Y/Y	10JUL2019	12SEP2019 (65)	Adverse Event: CVA INFARCT	Death, Cause of Death: Malignant disease	12SEP2019
0208-0008	ADIPemPlatinum	Y/Y/Y	16OCT2019	14APR2021 (547)	Progressive Disease: PD proven by local imaging review, Other: 11 MAY 2020 SCAN SHOWED PROGRESSION	Death, Cause of Death: Unknown	14APR2021
0209-0001	ADIPemPlatinum	Y/Y/Y	24APR2018	14NOV2019 (570)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	14NOV2019
0209-0003	ADIPemPlatinum	Y/Y/Y	19MAR2019	18SEP2019 (184)	Withdrawal from Treatment by Subject: INFECTION PLEUREX DRAIN SITE	Death, Cause of Death: Malignant disease	18SEP2019
0209-0004	ADIPemPlatinum	Y/Y/Y	02OCT2019	20JUL2022 (1023)	Adverse Event: ANAPHYLAXIS	Other: SUBJECT COMPLETED STUDY	
0209-0005	ADIPemPlatinum	Y/Y/Y	05NOV2019	11APR2020 (159)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	11APR2020
0210-0001	ADIPemPlatinum	Y/Y/Y	04JAN2021	29MAR2022 (450)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 11MAY2021	Death, Cause of Death: Malignant disease	29MAR2022
0211-0001	PlaceboPemPlatinum	Y/Y/Y	17JUL2019	16JUL2020 (366)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	16JUL2020

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0211-0002	PlaceboPemPlatinum	Y/Y/Y	07AUG2019	22FEB2020 (200)	Adverse Event: FATIGUE	Death, Cause of Death: Malignant disease	22FEB2020
0211-0003	ADIPemPlatinum	Y/Y/Y	02OCT2019	14JUL2022 (1017)	Progressive Disease: PD proven by local imaging review, Other: CT SCAN ON THE 02 APR 2020	Other: STUDY COMPLETION	
0211-0004	PlaceboPemPlatinum	Y/Y/Y	16OCT2019	02APR2020 (170)	Progressive Disease: PD proven by local imaging review, Other: DATE OF SCAN ON THE 14 FEB 2020	Death, Cause of Death: Malignant disease	02APR2020
0211-0005	PlaceboPemPlatinum	Y/Y/Y	06NOV2019	31MAR2020 (147)	Progressive Disease: PD proven by local imaging review, Other: 16 DEC 2019	Death, Cause of Death: Malignant disease	31MAR2020
0211-0006	PlaceboPemPlatinum	Y/Y/Y	14OCT2020	02JAN2021 (81)	Death, Cause of Death: Other, COVID 19 + PNEUMONITIS, Date of Scan with PD or Last Scan with SD: 24NOV2020	Death, Cause of Death: Other, COVID-19 + PNEUMONIA	02JAN2021
0211-0007	PlaceboPemPlatinum	Y/Y/Y	16DEC2020	15FEB2021 (62)	Death, Cause of Death: Unknown, Date of Scan with PD or Last Scan with SD: 17JAN2021	Death, Cause of Death: Unknown	15FEB2021
0212-0001	ADIPemPlatinum	Y/Y/Y	14AUG2018	12JUL2019 (333)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	12JUL2019
0212-0002	ADIPemPlatinum	Y/Y/Y	02OCT2018	14JAN2019 (105)	Physician Decision: RIGHT SIDED PNEUMONIA, Other: NOT PD	Death, Cause of Death: Other, PNEUMONIA ON BACKGROUND OF MESOTHELIOMA	14JAN2019
0212-0003	ADIPemPlatinum	Y/Y/Y	10OCT2018	21JAN2019 (104)	Progressive Disease: Clinical Progression, Other: 14/11/2018STABLE DISEASE	Death, Cause of Death: Malignant disease	21JAN2019
0212-0004	PlaceboPemPlatinum	Y/Y/Y	16JAN2019	23FEB2020 (404)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	23FEB2020
0212-0005	PlaceboPemPlatinum	Y/Y/Y	27MAR2019	17JUL2019 (113)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	17JUL2019
0212-0006	ADIPemPlatinum	Y/Y/Y	17JUL2019	26JUL2022 (1106)	Other: STUDY COMPLETION DATE OF LAST SCAN SHOWING STABLE DISEASE IS 20/JULY/2021	Other: COMPLETED STUDY	

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug



Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0212-0007	ADIPemPlatinum	Y/Y/Y	29JUL2019	06JAN2020 (162)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	06JAN2020
0212-0008	ADIPemPlatinum	Y/Y/Y	05AUG2019	19OCT2019 (76)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	19OCT2019
0212-0010	ADIPemPlatinum	Y/Y/Y	16MAR2020	02AUG2020 (140)	Adverse Event: FATIGUE	Death, Cause of Death: Malignant disease	02AUG2020
0212-0011	ADIPemPlatinum	Y/Y/Y	16JUN2020	24FEB2021 (254)	Progressive Disease: Clinical Progression, Date of Scan with PD or Last Scan with SD: 30JUL2020	Death, Cause of Death: Malignant disease	24FEB2021
0212-0012	PlaceboPemPlatinum	Y/Y/Y	09DEC2020	20JUL2021 (224)	Progressive Disease: Clinical Progression, Date of Scan with PD or Last Scan with SD: 04MAY2021	Death, Cause of Death: Malignant disease	20JUL2021
0214-0002	ADIPemPlatinum	Y/Y/Y	30JUN2021	09JUL2022 (375)	Adverse Event: RAISED CREATININE, Date of Scan with PD or Last Scan with SD: 14JUN2021	Death, Cause of Death: Malignant disease	09JUL2022
0217-0001	ADIPemPlatinum	Y/Y/Y	29JUL2020	14JUN2022 (686)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 08MAR2022	Death, Cause of Death: Malignant disease	14JUN2022
0217-0002	PlaceboPemPlatinum	Y/Y/Y	05MAY2021	28JUL2022 (450)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 29NOV2021	Other: STUDY COMPLETED	
0218-0001	PlaceboPemPlatinum	Y/Y/Y	01JUN2020	23FEB2021 (268)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 22OCT2020	Death, Cause of Death: Malignant disease	23FEB2021
0218-0002	ADIPemPlatinum	Y/Y/Y	01JUN2020	18JUN2020 (18)	Death, Cause of Death: Unknown, SUDDEN DEATH ON CHEMOTHERAPY, CAUSE UNKNOWN	Death, Cause of Death: Unknown	18JUN2020
0218-0003	ADIPemPlatinum	Y/Y/Y	17JUN2020	13AUG2021 (423)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 18MAY2021	Death, Cause of Death: Malignant disease	13AUG2021

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0218-0005	ADIPemPlatinum	Y/Y/Y	29JUN2020	21APR2021 (297)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 29OCT2020	Death, Cause of Death: Malignant disease	21APR2021
0218-0006	PlaceboPemPlatinum	Y/Y/Y	14JUL2020	20APR2021 (281)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 10NOV2020	Death, Cause of Death: Malignant disease	20APR2021
0218-0007	PlaceboPemPlatinum	Y/Y/Y	20JUL2020	18NOV2020 (122)	Progressive Disease: Clinical Progression, Date of Scan with PD or Last Scan with SD: 08OCT2020	Death, Cause of Death: Malignant disease	18NOV2020
0218-0008	PlaceboPemPlatinum	Y/Y/Y	04AUG2020	12JUN2021 (313)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 23MAR2021	Death, Cause of Death: Malignant disease	12JUN2021
0218-0012	PlaceboPemPlatinum	Y/Y/Y	21SEP2020	07DEC2020 (78)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 02NOV2020	Death, Cause of Death: Malignant disease	07DEC2020
0218-0013	ADIPemPlatinum	Y/Y/Y	29SEP2020	24JUN2022 (634)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 18MAY2021	Other: STUDY COMPLETION	
0218-0014	ADIPemPlatinum	Y/Y/Y	20OCT2020	09MAY2021 (202)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 22APR2021	Death, Cause of Death: Malignant disease	09MAY2021
0218-0015	ADIPemPlatinum	Y/Y/Y	19JAN2021	27FEB2021 (40)	Death, Cause of Death: Malignant disease, Date of Scan with PD or Last Scan with SD: 25FEB2021	Death, Cause of Death: Malignant disease	27FEB2021
0218-0016	ADIPemPlatinum	Y/Y/Y	02MAR2021	18NOV2021 (262)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 12OCT2021	Death, Cause of Death: SAE	18NOV2021
0218-0018	ADIPemPlatinum	Y/Y/Y	30MAR2021	04JUL2021 (97)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 17JUN2021	Death, Cause of Death: Malignant disease	04JUL2021

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0218-0019	PlaceboPemPlatinum	Y/Y/Y	20APR2021	21APR2022 (367)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 19OCT2021	Death, Cause of Death: Unknown	21APR2022
0219-0001	ADIPemPlatinum	Y/Y/Y	11NOV2020	16MAR2021 (126)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 09DEC2020	Death, Cause of Death: Malignant disease	16MAR2021
0219-0002	ADIPemPlatinum	Y/Y/Y	06JAN2021	04MAY2021 (119)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 17FEB2021	Death, Cause of Death: Malignant disease	04MAY2021
0219-0003	PlaceboPemPlatinum	Y/Y/Y	20JAN2021	12DEC2021 (327)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 26MAY2021	Death, Cause of Death: Malignant disease	12DEC2021
0219-0004	PlaceboPemPlatinum	Y/Y/Y	20JAN2021	26JUL2022 (553)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 19MAY2021	Death, Cause of Death: Unknown	26JUL2022
0219-0005	ADIPemPlatinum	Y/Y/Y	24MAR2021	14APR2022 (387)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 21JUL2021	Death, Cause of Death: Unknown	14APR2022
0219-0006	ADIPemPlatinum	Y/Y/Y	21APR2021	02FEB2022 (288)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 17NOV2021	Death, Cause of Death: Malignant disease	02FEB2022
0301-0001	PlaceboPemPlatinum	Y/Y/Y	17DEC2018	20MAR2019 (94)	Progressive Disease: Clinical Progression	Death, Cause of Death: Malignant disease	20MAR2019
0301-0002	PlaceboPemPlatinum	Y/Y/Y	17DEC2018	14NOV2021 (1064)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	14NOV2021
0301-0003	PlaceboPemPlatinum	Y/Y/Y	29JAN2019	21MAR2019 (52)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	21MAR2019
0301-0004	PlaceboPemPlatinum	Y/Y/Y	12MAR2019	08JUL2020 (485)	Progressive Disease: Clinical Progression	Death, Cause of Death: Malignant disease	08JUL2020

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0301-0005	PlaceboPemPlatinum	Y/Y/Y	02JUL2019	12JUL2020 (377)	Withdrawal from Treatment by Subject	Death, Cause of Death: Malignant disease	12JUL2020
0301-0006	PlaceboPemPlatinum	Y/Y/Y	23JUL2019	20DEC2020 (517)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	20DEC2020
0301-0007	PlaceboPemPlatinum	Y/Y/Y	15OCT2019	01JUN2020 (231)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	01JUN2020
0302-0001	PlaceboPemPlatinum	Y/Y/Y	22JAN2020	23FEB2022 (764)	Progressive Disease: Clinical Progression, Date of Scan with PD or Last Scan with SD: 15JUL2020	Death, Cause of Death: Malignant disease	23FEB2022
0303-0001	ADIPemPlatinum	Y/Y/Y	03MAR2020	18NOV2020 (261)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 23OCT2020	Death, Cause of Death: Malignant disease	18NOV2020
0303-0002	ADIPemPlatinum	Y/Y/Y	29JUL2020	06JAN2021 (162)	Adverse Event: FALL/ COLLAPSE, Other: STABLE DISEASE, Date of Scan with PD or Last Scan with SD: 01SEP2020	Death, Cause of Death: Malignant disease	06JAN2021
0304-0001	PlaceboPemPlatinum	Y/Y/Y	05JUN2018	12JUL2018 (38)	Adverse Event: MYOCARDIAL INFARCTION	Death, Cause of Death: Unknown	12JUL2018
0304-0002	ADIPemPlatinum	Y/Y/Y	05FEB2020	08MAR2020 (33)	Adverse Event: SUDDEN DEATH	Death, Cause of Death: Unknown	08MAR2020
0304-0003	PlaceboPemPlatinum	Y/Y/Y	26MAY2020	12SEP2021 (475)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 04MAR2021	Death, Cause of Death: Malignant disease	12SEP2021
0304-0004	PlaceboPemPlatinum	Y/Y/Y	30JUN2020	03NOV2020 (127)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 21SEP2020	Death, Cause of Death: Malignant disease	03NOV2020
0305-0001	ADIPemPlatinum	Y/Y/Y	30JUL2018	09APR2020 (620)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	09APR2020
0305-0002	PlaceboPemPlatinum	Y/Y/Y	24JUN2019	21AUG2019 (59)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	21AUG2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0305-0004	ADIPemPlatinum	Y/Y/Y	23MAR2020	29JUN2021 (464)	Adverse Event: ANAPHYLAXIS, Date of Scan with PD or Last Scan with SD: 17JUN2020	Death, Cause of Death: Malignant disease	29JUN2021
0305-0005	ADIPemPlatinum	Y/Y/Y	16NOV2020	28NOV2021 (378)	Adverse Event: ENTEROCOLITIS, Date of Scan with PD or Last Scan with SD: 22DEC2020	Death, Cause of Death: Malignant disease	28NOV2021
0502-0001	ADIPemPlatinum	Y/Y/Y	02OCT2019	01AUG2022 (1035)	Adverse Event: NEUROPATHY, Other: 30-MAR-2020	Other: STUDY COMPLETION	
0502-0002	ADIPemPlatinum	Y/Y/Y	21OCT2019	09JUL2020 (263)	Progressive Disease: PD proven by local imaging review, Other: 01 APR 2020	Death, Cause of Death: Malignant disease	09JUL2020
0502-0003	ADIPemPlatinum	Y/Y/Y	18MAR2020	10JAN2021 (299)	Progressive Disease: PD proven by local imaging review, Other: DISEASE PROGRESSION, Date of Scan with PD or Last Scan with SD: 08MAY2020	Death, Cause of Death: Malignant disease	10JAN2021
0502-0004	ADIPemPlatinum	Y/Y/Y	27JAN2021	01AUG2022 (552)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 23FEB2022	Other: STUDY COMPLETION	
0502-0005	ADIPemPlatinum	Y/Y/Y	24MAR2021	01AUG2022 (496)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 21SEP2021	Other: STUDY COMPLETION	
0502-0006	PlaceboPemPlatinum	Y/Y/Y	31MAR2021	01AUG2022 (489)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 16SEP2021	Other: STUDY COMPLETION	
0502-0008	ADIPemPlatinum	Y/Y/Y	16JUN2021	03AUG2022 (414)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 07DEC2021	Death, Cause of Death: Malignant disease	03AUG2022
0502-0010	ADIPemPlatinum	Y/Y/Y	16AUG2021	06MAY2022 (264)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 08NOV2021	Death, Cause of Death: Malignant disease	06MAY2022
0502-0011	PlaceboPemPlatinum	Y/Y/Y	16AUG2021	01AUG2022 (351)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 07APR2022	Other: STUDY COMPLETION	

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

**Listing 16.2.1**  
**Subject Disposition**

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0503-0001	PlaceboPemPlatinum	Y/Y/Y	27MAY2019	07MAR2020 (286)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Malignant disease	07MAR2020
0503-0003	PlaceboPemPlatinum	Y/Y/Y	25SEP2019	14OCT2019 (20)	Adverse Event: SEPTIC SHOCK	Death, Cause of Death: SAE	14OCT2019
0505-0001	PlaceboPemPlatinum	Y/Y/Y	27APR2020	17FEB2021 (297)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 16JUN2020	Death, Cause of Death: Malignant disease	17FEB2021
0505-0002	PlaceboPemPlatinum	Y/Y/Y	11JAN2021	09DEC2021 (333)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 09JUL2021	Death, Cause of Death: Malignant disease	09DEC2021
0506-0001	ADIPemPlatinum	Y/Y/Y	07JUN2019	01OCT2019 (117)	Death, Cause of Death: Malignant disease	Death, Cause of Death: Other, PROGRESSION DISEASE	01OCT2019
0506-0002	PlaceboPemPlatinum	Y/Y/Y	17JUN2019	15NOV2020 (518)	Progressive Disease: PD proven by local imaging review	Death, Cause of Death: Other, COVID-19 PNEUMONIA	15NOV2020
0506-0004	PlaceboPemPlatinum	Y/Y/Y	25MAR2020	05MAY2020 (42)	Death, Cause of Death: Malignant disease	Death, Cause of Death: Malignant disease	05MAY2020
0506-0005	PlaceboPemPlatinum	Y/Y/Y	06MAY2020	06MAR2021 (305)	Progressive Disease: Clinical Progression, Date of Scan with PD or Last Scan with SD: 03MAR2021	Death, Cause of Death: Malignant disease	06MAR2021
0506-0006	ADIPemPlatinum	Y/Y/Y	26AUG2020	21MAY2021 (269)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 03MAR2021	Death, Cause of Death: Malignant disease	21MAY2021
0506-0008	PlaceboPemPlatinum	Y/Y/Y	07APR2021	18AUG2022 (499)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 06OCT2021	Other: STUDY COMPLETION	
0506-0009	ADIPemPlatinum	Y/Y/Y	09JUN2021	24DEC2021 (199)	Progressive Disease: PD proven by local imaging review, Date of Scan with PD or Last Scan with SD: 13OCT2021	Death, Cause of Death: Malignant disease	24DEC2021
0506-0010	ADIPemPlatinum	Y/Y/Y	28JUL2021	19AUG2022 (388)	Other: PT WILL CONTINUE IN THE EXPANDED PHASE, Date of Scan with PD or Last Scan with SD: 13JUL2022	Other: PT WILL CONTINUE IN THE BLINDED EXPANDED PHASE	

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug

Listing 16.2.1  
Subject Disposition

Subject ID	Treatment Group	Safety <sup>[1]</sup> /ITT <sup>[2]</sup> /PP <sup>[3]</sup> Population	Date of First Dose	Date of Last Contact or Visit (Study Day <sup>[4]</sup> )	Primary Reason for Discontinuing Study Treatment	Primary Reason for Study Termination	Date of Death
0508-0001	PlaceboPemPlatinum	Y/Y/Y	18MAY2020	21AUG2020 (96)	Adverse Event: PNEUMOTHORAX, Date of Scan with PD or Last Scan with SD: 05AUG2020	Death, Cause of Death: Malignant disease	21AUG2020
0509-0002	PlaceboPemPlatinum	Y/Y/Y	18SEP2018	07JUN2019 (263)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	07JUN2019
0510-0001	PlaceboPemPlatinum	Y/Y/Y	26FEB2020	27AUG2022 (914)	Withdrawal from Treatment by Subject, Date of Scan with PD or Last Scan with SD: 23APR2020	Death, Cause of Death: Malignant disease	27AUG2022
0511-0001	ADIPemPlatinum	Y/Y/Y	09APR2019	05MAR2020 (332)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	05MAR2020
0511-0002	PlaceboPemPlatinum	Y/Y/Y	14MAY2019	24JAN2020 (256)	Progressive Disease: Clinical Progression	Death, Cause of Death: Malignant disease	24JAN2020
0511-0003	PlaceboPemPlatinum	Y/Y/Y	06AUG2019	04MAR2020 (212)	Progressive Disease: Clinical Progression	Death, Cause of Death: Malignant disease	04MAR2020
0511-0004	PlaceboPemPlatinum	Y/Y/Y	22SEP2020	07JUN2022 (624)	Withdrawal from Treatment by Subject, Date of Scan with PD or Last Scan with SD: 11FEB2021	Other: STUDY COMPLETION	
0511-0005	PlaceboPemPlatinum	Y/Y/Y	20OCT2020	18JUL2022 (637)	Withdrawal from Treatment by Subject, Date of Scan with PD or Last Scan with SD: 03MAR2021	Other: STUDY COMPLETION	
0511-0006	PlaceboPemPlatinum	Y/Y/Y	22DEC2020	20MAY2021 (150)	Physician Decision, Date of Scan with PD or Last Scan with SD: 24MAR2021	Death, Cause of Death: Malignant disease	20MAY2021
1201-0001	PlaceboPemPlatinum	Y/Y/Y	31OCT2018	04FEB2019 (97)	Death, Cause of Death: SAE, PNEUMONIA	Death, Cause of Death: SAE	04FEB2019
1206-0001	PlaceboPemPlatinum	Y/Y/Y	06FEB2018	03OCT2018 (240)	Progressive Disease: PD proven by central imaging review	Death, Cause of Death: Malignant disease	03OCT2018
1206-0002	PlaceboPemPlatinum	Y/Y/Y	14MAY2018	09JUL2018 (57)	Adverse Event: ACUTE RENAL FAILURE	Death, Cause of Death: SAE	09JUL2018
1206-0003	PlaceboPemPlatinum	Y/Y/Y	01APR2019	08MAY2019 (38)	Physician Decision	Death, Cause of Death: SAE	08MAY2019

Abbreviations: ITT = Intent-to-Treat; PD = progressive disease; PP = Per-Protocol; SD = stable disease; Y = yes

<sup>[1]</sup> Safety population includes all randomized subjects who received at least one dose of the study medication. Assignment of subjects to treatment group is based on the treatment actually received.

<sup>[2]</sup> ITT population includes all randomized subjects. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[3]</sup> PP Population includes all ITT subjects who have no major protocol violations that may potentially affect the primary and secondary efficacy measures. Assignment of subjects to treatment group is based on the randomized treatment assignment.

<sup>[4]</sup> Time (days) relative to date of first dose of study drug